Of over 170 types of RNA modifications discovered, N⁶-methyladenosine (m⁶A) is the most actively studied. m⁶A confers oncogenic potential, maintains cancer stem cells, and is associated with cancer-related outcomes. The role of RNA modifications including m¹A is poorly understood. m¹A is abundant in transfer and ribosomal RNAs but has also been found on messenger RNAs. m¹A stabilizes these RNA species to regulate essential biological processes including translation and ribosome biogenesis, which are frequently dysregulated in cancers. However, the role of aberrant m¹A RNA methylation in cancer development and its utility in predicting clinical outcomes is currently unclear. Understanding the function of m¹A RNA methylation in diverse cancers requires the characterization of genetic alterations and aberrant expression of m¹A regulatory genes. These genes include m¹A writers (TRM61A, TRIM61B, TRIMT61B, TRMT10C), erasers (ALKBH1, ALKBH3) and readers (YTHDF1, YTHDF2, YTHDF3 and YTHDC1). Here, we present the frequency of molecular abnormalities affecting m¹A regulatory genes and their association with cancer-related pathways, prognosis, and tumor immune cell infiltration across 33 types of human cancers.